TipRanks
Cardiol Therapeutics (DE:CT9)
FRANKFURT:CT9
Germany Market
CT9
Cardiol Therapeutics
RESEARCH TOOLSreports

Cardiol Therapeutics (CT9) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

CT9 Analyst Ratings

Strong Buy
3Ratings
Strong Buy
3 Buy
0 Hold
0 Sell
Based on 3 analysts giving stock ratings to
Cardiol
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CT9 Stock 12 Month Forecast

Average Price Target

€8.79
▲(377.79% Upside)
Based on 3 Wall Street analysts offering 12 month price targets for Cardiol Therapeutics in the last 3 months. The average price target is €8.79 with a high forecast of €9.67 and a low forecast of €7.91. The average price target represents a 377.79% change from the last price of €1.84.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"€10","-1":"-€1","1.75":"€1.75","4.5":"€4.5","7.25":"€7.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9.670431650000001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€9.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.791301500000001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€8.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.91217135,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€7.91</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.75,4.5,7.25,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.7,2.313110126923077,2.9262202538461537,3.539330380769231,4.152440507692308,4.765550634615385,5.378660761538462,5.991770888461539,6.604881015384616,7.217991142307693,7.83110126923077,8.444211396153847,9.057321523076924,{"y":9.670431650000001,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.7,2.2454847307692307,2.7909694615384617,3.3364541923076922,3.8819389230769232,4.427423653846154,4.972908384615385,5.518393115384616,6.063877846153847,6.609362576923078,7.154847307692309,7.70033203846154,8.24581676923077,{"y":8.791301500000001,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.7,2.1778593346153845,2.6557186692307693,3.1335780038461536,3.6114373384615384,4.089296673076923,4.567156007692308,5.045015342307693,5.522874676923077,6.000734011538462,6.478593346153847,6.956452680769232,7.434312015384616,{"y":7.91217135,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.886,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.842,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.91,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.868,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.751,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.751,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.811,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.094,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.12,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.05,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.861,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.98,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.7,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€9.67Average Price Target€8.79Lowest Price Target€7.91
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on DE:CT9
Edward Nash
Canaccord Genuity
Canaccord Genuity
€8.79
Buy
377.79%
Upside
Reiterated
09/23/26
Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (NASDAQ: ARCT), Tango Therapeutics (NASDAQ: TNGX) and Cardiol Therapeutics (NASDAQ: CRDL)
H.C. Wainwright Analyst forecast on DE:CT9
Brandon Folkes
H.C. Wainwright
H.C. Wainwright
€7.91
Buy
330.01%
Upside
Reiterated
09/21/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Cardiol Therapeutics (NASDAQ: CRDL), Tyra Bioscience (NASDAQ: TYRA) and Alibaba Health Information Technology (Other OTC: ALBHF)
B. Riley Securities Analyst forecast on DE:CT9
Mayank Mamtani
B. Riley Securities
B. Riley Securities
€9.67
Buy
425.57%
Upside
Initiated
08/26/26
Cardiol Therapeutics initiated with a Buy at B. RileyCardiol Therapeutics initiated with a Buy at B. Riley
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on DE:CT9
Edward Nash
Canaccord Genuity
Canaccord Genuity
€8.79
Buy
377.79%
Upside
Reiterated
09/23/26
Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (NASDAQ: ARCT), Tango Therapeutics (NASDAQ: TNGX) and Cardiol Therapeutics (NASDAQ: CRDL)
H.C. Wainwright Analyst forecast on DE:CT9
Brandon Folkes
H.C. Wainwright
H.C. Wainwright
€7.91
Buy
330.01%
Upside
Reiterated
09/21/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Cardiol Therapeutics (NASDAQ: CRDL), Tyra Bioscience (NASDAQ: TYRA) and Alibaba Health Information Technology (Other OTC: ALBHF)
B. Riley Securities Analyst forecast on DE:CT9
Mayank Mamtani
B. Riley Securities
B. Riley Securities
€9.67
Buy
425.57%
Upside
Initiated
08/26/26
Cardiol Therapeutics initiated with a Buy at B. RileyCardiol Therapeutics initiated with a Buy at B. Riley
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
MDWDMediwound
OCULOcular Therapeutix
GHGuardant Health
HROWHarrow Health
DNLIDenali Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cardiol Therapeutics

3 Months
Edward NashCanaccord Genuity
Success Rate
10/21 ratings generated profit
48%
Average Return
+5.17%
Copying Edward Nash's trades and holding each position for 3 Months would result in 47.62% of your transactions generating a profit, with an average return of +5.17% per trade.
1 Year
Brandon FolkesH.C. Wainwright
Success Rate
8/12 ratings generated profit
67%
Average Return
+34.87%
Copying Brandon Folkes's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +34.87% per trade.
2 Years
Brandon FolkesH.C. Wainwright
Success Rate
10/12 ratings generated profit
83%
Average Return
+44.42%
Copying Brandon Folkes's trades and holding each position for 2 Years would result in 83.33% of your transactions generating a profit, with an average return of +44.42% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CT9 Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
7
7
5
5
7
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
7
5
5
7
In the current month, CT9 has received 7 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CT9 average Analyst price target in the past 3 months is 8.79.
Each month's total comprises the sum of three months' worth of ratings.

CT9 Financial Forecast

CT9 Earnings Forecast

Next quarter’s earnings estimate for CT9 is -€0.05 with a range of -€0.07 to -€0.04. The previous quarter’s EPS was -€0.03. CT9 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year CT9 has Performed in-line its overall industry.
Next quarter’s earnings estimate for CT9 is -€0.05 with a range of -€0.07 to -€0.04. The previous quarter’s EPS was -€0.03. CT9 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year CT9 has Performed in-line its overall industry.

CT9 Sales Forecast

Next quarter’s sales forecast for CT9 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. CT9 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year CT9 has Performed in-line its overall industry.
Next quarter’s sales forecast for CT9 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. CT9 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year CT9 has Performed in-line its overall industry.

CT9 Stock Forecast FAQ

What is DE:CT9’s average 12-month price target, according to analysts?
Based on analyst ratings, Cardiol Therapeutics’s 12-month average price target is 8.79.
    What is DE:CT9’s upside potential, based on the analysts’ average price target?
    Cardiol Therapeutics has 377.79% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Cardiol Therapeutics a Buy, Sell or Hold?
          Cardiol Therapeutics has a consensus rating of Strong Buy, which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Cardiol Therapeutics’s share price target?
            The average share price target for Cardiol Therapeutics is 8.79. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €9.67 ,and the lowest forecast is €7.91. The average share price target represents 377.79% Increase from the current price of €1.84.
              What do analysts say about Cardiol Therapeutics?
              Cardiol Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
                How can I buy shares of Cardiol Therapeutics?
                To buy shares of DE:CT9, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.